PiperSandler kept its Overweight rating on Five9 (NASDAQ:FIVN) but reduced the price target to $35 from $47. Last month, Five9 said it was planning to reduce its global workforce by 7% as part of ...
On Thursday, PiperSandler reaffirmed its Overweight rating on Ocular Therapeutix (NASDAQ:OCUL) shares with a steady price target of $15.00. The firm's focus was drawn to the gene therapy program ...
Investors are facing the busiest quarterly rebalancing in about four years on Friday in a shake-up that could affect roughly $250 billion worth of stocks, according to a team of equity analysts at ...
Some results have been hidden because they may be inaccessible to you